Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.

G. Novack

DOI: https://doi.org/10.1016/S0002-9394(00)00579-1

2000-11-01

Abstract:

What problem does this paper attempt to address?

Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer

Paras Shah,William R. Taylor,Brianna J. Negaard,Benjamin R. Gochanour,Douglas W. Mahoney,Sara S. Then,Mary E. Devens,Patrick H. Foote,Karen A. Doering,Kelli N. Burger,Brandon Nikolai,Michael W. Kaiser,Hatim T. Allawi,John C. Cheville,John B. Kisiel,Matthew T. Gettman

DOI: https://doi.org/10.3390/life14081024

2024-08-19

Life

Abstract:Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of patients with biopsy-proven PCa relative to healthy controls and further studied discrimination of clinically significant PCa (csPCa) from healthy controls and Gleason 6 cancers. Methods: To evaluate the panel, urine from 24 healthy male volunteers with no clinical suspicion for PCa and 24 men with biopsy-confirmed disease across all Gleason scores was collected. Blinded to clinical status, DNA from the supernatant was analyzed for methylation signal within specific DNA sequences across 14 genes (HES5, ZNF655, ITPRIPL1, MAX.chr3.6187, SLCO3A1, CHST11, SERPINB9, WNT3A, KCNB2, GAS6, AKR1B1, MAX.chr3.8028, GRASP, ST6GALNAC2) by target enrichment long-probe quantitative-amplified signal assays. Results: Utilizing an overall specificity cut-off of 100% for discriminating normal controls from PCa cases across the MDM panel resulted in 71% sensitivity (95% CI: 49–87%) for PCa detection (4/7 Gleason 6, 8/12 Gleason 7, 5/5 Gleason 8+) and 76% (50–92%) for csPCa (Gleason ≥ 7). At 100% specificity for controls and Gleason 6 patients combined, MDM panel sensitivity was 59% (33–81%) for csPCa (5/12 Gleason 7, 5/5 Gleason 8+). Conclusions: MDMs assayed in urine offer high sensitivity and specificity for detection of clinically significant prostate cancer. Prospective evaluation is necessary to estimate discrimination of patients as first-line screening and as an adjunct to prostate-specific antigen (PSA) testing.

biology
Abstract 1264: A targeted methylation-based multi-cancer early detection blood test preferentially detects high-grade prostate cancer and minimizes overdiagnosis

Brandan Mahal,Matthew Margolis,Earl Hubbell,Cheng Chen,Jeffrey M. Venstrom,John Abran,Jordan J. Karlitz,Alexander W. Wyatt,Eric A. Klein

DOI: https://doi.org/10.1158/1538-7445.am2024-1264

IF: 11.2

2024-03-24

Cancer Research

Abstract:Background: Indolent prostate cancer (PCa) is prevalent in men in the intended use population (adults aged 50-79 years) for blood-based multi-cancer early detection (MCED) tests. It is thus important to understand detectability of PCa by MCED tests across the spectrum of disease aggressiveness, including detection of indolent disease. Methods: PCa detectability by a targeted methylation-based MCED test that interrogates circulating cfDNA was assessed in 2 studies: 1) the Circulating Cell-free Genome Atlas (CCGA, NCT02889978), a case-control study (Substudy 3) that demonstrated detection of a shared cancer signal across > 50 cancer types and accurate prediction of cancer signal origin (CSO) with an observed false positive rate of 0.5%; and 2) PATHFINDER (PF, NCT04241796), a return of results cohort study in the intended use population without clinical suspicion of cancer. MCED test performance was assessed by Gleason grade group (GG) and clinical stage, and the association between tumor methylated fraction (TMeF) and cancer detectability was investigated. Results: The CCGA3 study included 420 recently diagnosed PCa cases with a median age of 65 years (IQR, 59-70). Test sensitivity for PCa was 11.2% (47/420), and CSO accuracy was 91.5% (43/47). Median PSA was higher in detected cases (14 ng/dL, IQR 7-38 vs 6 ng/dL, IQR 5-9, p < 0.05). The MCED test detected no low grade (GG1, 0/58), 1.9% (3/157) of favorable intermediate grade (GG2), 5.1% (4/78) of unfavorable intermediate grade (GG3), and 31.9% (36/113) of high grade (GG4 & GG5) cancers. Clinical staging showed detection of 3.2% (3/95) of Stage I, 4.7% (11/235) of Stage II, 14.9% (7/47) of Stage III, and 81.5% (22/27) of Stage IV cases. Non-detected cases had better overall survival (HR 0.263, CI 0.104 - 0.533, p<0.05), and detected cases had similar survival (HR 0.672, CI 0.323 - 1.21, p=0.2) compared to SEER estimates matched for age, stage and GG. Median TMeF was higher for detected cases (0.002106, IQR 0.000350 - 0.024376 vs 0.000024, IQR 0.00001 - 0.000038, p < 0.05). Performance was similar in PF (median age 66 years, IQR 58 -70) with overall sensitivity for PCa of 5.9% (1/17), including no (0/12) detected GG1-2 cases and one of five GG3-5 cases. No Stage I or II (0/15) and 1/2 (50%) Stage III & IV cases were detected. Conclusion: In two independent prospective studies, this MCED test preferentially detected high grade, clinically significant PCa. A cancer signal detected test result with a prostate CSO prediction generally indicates the presence of aggressive PCa and should lead to a prompt diagnostic work-up. Use of this test in population-based screening programs is unlikely to exacerbate overdiagnosis of indolent PCa. Citation Format: Brandan Mahal, Matthew Margolis, Earl Hubbell, Cheng Chen, Jeffrey M. Venstrom, John Abran, Jordan J. Karlitz, Alexander W. Wyatt, Eric A. Klein. A targeted methylation-based multi-cancer early detection blood test preferentially detects high-grade prostate cancer and minimizes overdiagnosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1264.

oncology
Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients

Friedemann,Jandeck,Tautz,Gutewort,von Rein,Sukocheva,Fuessel,Menschikowski

DOI: https://doi.org/10.3390/cancers16071324

2024-03-29

Cancers

Abstract:Current prostate carcinoma (PCa) biomarkers, including total prostate-specific antigen (tPSA), have unsatisfactory diagnostic sensitivity and specificity resulting in overdiagnosis and overtreatment. Previously, we described an optimised bias-based preamplification–digital droplet PCR (OBBPA-ddPCR) technique, which detects tumour DNA in blood-derived cell-free DNA (cfDNA) of cancer patients. The current study investigated the performance of newly developed OBBPA-ddPCR-based biomarkers. Blood plasma samples from healthy individuals (n = 90, controls) and PCa (n = 39) and benign prostatic hyperplasia patients (BPH, n = 40) were analysed. PCa and BPH patients had tPSA values within a diagnostic grey area of 2–15 ng/mL, for whom further diagnostic validation is most crucial. Methylation levels of biomarkers RASSF1A, MIR129-2, NRIP3, and SOX8 were found significantly increased in PCa patients compared to controls. By combining classical PCa risk factors (percentage of free PSA compared to tPSA (QfPSA) and patient's age) with cfDNA-based biomarkers, we developed PCa risk scores with improved sensitivity and specificity compared to established tPSA and QfPSA single-marker analyses. The diagnostic specificity was increased to 70% with 100% sensitivity for clinically significant PCa patients. Thus, prostate biopsies could be avoided for 28 out of 40 BPH patients. In conclusion, the newly developed risk scores may help to confirm the clinical decision and prevent unnecessary prostate biopsy.

oncology
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation

Gian Marco Franceschini,Orsetta Quaini,Kei Mizuno,Francesco Orlando,Yari Ciani,Sheng-Yu Ku,Michael Sigouros,Emily Rothmann,Alicia Alonso,Matteo Benelli,Caterina Nardella,Joonghoon Auh,Dory Freeman,Brian Hanratty,Mohamed Adil,Olivier Elemento,Scott T. Tagawa,Felix Y. Feng,Orazio Caffo,Consuelo Buttigliero,Umberto Basso,Peter S. Nelson,Eva Corey,Michael C. Haffner,Gerhardt Attard,Ana Aparicio,Francesca Demichelis,Himisha Beltran

DOI: https://doi.org/10.1158/2159-8290.cd-23-0754

IF: 28.2

2024-01-12

Cancer Discovery

Abstract:Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. We developed a targeted DNA methylation assay to detect CRPC-NE using plasma cell-free DNA (cfDNA). The assay quantifies tumor content and provides a phenotype evidence score that captures diverse CRPC phenotypes, leveraging regions to inform transcriptional state. We tested the design in independent clinical cohorts (n = 222 plasma samples) and qualified it achieving an AUC > 0.93 for detecting pathology-confirmed CRPC-NE (n = 136). Methylation-defined cfDNA tumor content was associated with clinical outcomes in two prospective phase II clinical trials geared towards aggressive variant CRPC and CRPC-NE. These data support the application of targeted DNA methylation for CRPC-NE detection and patient stratification. Significance: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell–free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively.

oncology
Highly Specific Multiplex DNA Methylation Detection for Liquid Biopsy of Colorectal Cancer

Dewen Zhu,Jinlei Li,Wenwen Zhang,Yishuai Wang,Huidong Wang,Ruoyan Fei,Qian Ye,Danli Peng,Ju Luan,Chang Xu,Xiaoli Wu,Dan Huang,Chunming Ding,Shengnan Jin

DOI: https://doi.org/10.1016/j.cca.2024.120026

2024-01-01

Abstract:BACKGROUND:Circulating tumor DNA (ctDNA) has emerged as a useful biomarker for cancer detection and prognosis. In this study, we developed a strategy for developing a highly specific multiplex qPCR assay to detect methylated ctDNA in the blood of colorectal cancer (CRC) patients and investigated the potential use for the detection and prognosis of CRC. METHODS:Bisulfite conversion and amplicon sequencing were used to confirm potential CRC-specific DNA methylation markers. The selected DNA methylation candidates were validated by qMSP. The six best-performing markers were used to develop a new single-tube multiplex quantitative methylation-specific PCR assay (mqMSP). The mqMSP assay was applied to analyze plasma samples from 114 CRC patients, 47 patients with advanced adenoma, 45 patients with benign polyps, and 57 healthy controls. The clinical performance of the assay and associations with clinical outcomes were assessed. RESULTS:Six DNA methylation biomarkers were confirmed to be specifically hypermethylated in CRC tumor tissues. The newly developed mqMSP assay detected CRC with extremely high specificity (specificity of 98.2 %, with sensitivity of 67.5 %). The detection rate of ctDNA was significantly correlated with tumor size and clinical stage, with ctDNA methylation levels in the blood markedly increased with larger tumor size, poor differentiation, and advanced stage. Moreover, high preoperative methylated ctDNA level was associated with worse recurrence-free survival and overall survival. CONCLUSION:We provided a strategy for identification of multiple highly-specific DNA methylation markers for designing multiplex DNA methylation assays for liquid biopsies of CRC. The newly developed assay has potential for CRC early detection, and prognosis.
Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach

Thomas Büttner,Dimo Dietrich,Romina Zarbl,Niklas Klümper,Jörg Ellinger,Philipp Krausewitz,Manuel Ritter

DOI: https://doi.org/10.3390/cancers16030482

2024-01-24

Cancers

Abstract:Background: Metastatic prostate cancer (mPCA) poses challenges in treatment response assessment, particularly in cases where prostate-specific antigen (PSA) levels do not reliably indicate a response. Liquid biopsy, focusing on circulating cell-free DNA (ccfDNA) methylation analysis as a proxy for circulating tumor DNA, offers a non-invasive and cost-effective approach. This study explores the potential of two methylation markers, short stature homeobox 2 (SHOX2) and Septin 9 (SEPT9), as on-mPCA-treatment biomarkers. Methods: Plasma samples were collected from 11 mPCA patients undergoing various treatments. Quantitative assessment of hypermethylated SHOX2 (mSHOX2) and SEPT9 (mSEPT9) levels in ccfDNA was conducted through methylation-specific real-time PCR. Early and overall dynamics of PSA, mSHOX2, and mSEPT9 were analyzed. Statistical evaluation employed Wilcoxon tests. Results: mSHOX2 demonstrated a significant decline post-treatment in patients with a radiographic treatment response as well as in an early treatment setting. mSEPT9 and PSA exhibited non-significant declines. In individual cases, biomarker dynamics revealed unique patterns compared to PSA. Discussion: mSHOX2 and mSEPT9 exhibit dynamics on mPCA treatment. This proof-of-concept study lays the groundwork for further investigation into these markers as valuable additions to treatment response monitoring in mPCA. Further validation in larger cohorts is essential for establishing clinical utility.

oncology
Accurate early-stage colorectal cancer detection through analysis of cell-free circulating tumor DNA (ctDNA) methylation patterns.

James M. Kinross,Pol Canal-Noguer,Marko Chersicola,Primož Knap,Marko Bitenc,Alexandre Perera-Lluna,Michael H. A. Roehrl,Kristi Kruusmaa

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.3606

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:3606 Background: Colorectal cancer (CRC) screening programs suffer from poor uptake and biomarkers have limited diagnostic accuracy. The measurement of the methylation status of tumor-derived cell-free DNA in plasma may address these challenges. We used a targeted methylation panel, tumor-derived signal deduction and machine learning algorithm to refine a blood test for the detection of early-stage CRC. Methods: This was a prospective, international multicenter observational cohort study. Plasma samples were collected either prior to a scheduled colonoscopy as part of standard colorectal cancer screening or prior to colonic surgery for primary CRC. Differentially methylated regions (DMRs) were initially selected by analyzing CRC and control tissue samples with whole genome bisulfite sequencing. A targeted sequencing assay was designed to capture these DMRs in plasma ctDNA. Individual sequencing reads were evaluated for cancer-specific methylation signal and scores calculated for each DMR in a sample. A panel of methylation scores originating from 203 DMRs was used in a prediction model building and validated in a test cohort of patients. Results: Calculated scores were used to train a machine learning model on 68 ctDNA samples from 18 early stage (I-II) and 16 late-stage (III-IV) CRC patients and 34 age, BMI, gender and country of origin matched neoplasia-free controls (median age 63 [50-74], mean BMI 27 [19.5-37], female 50%, Spanish and Ukrainian population, distal cancers 50%). This model was then applied to an independent set of subjects from Spanish, Ukraine and Germany, including 36 stage I-IV cancer patients (median age 61.5 [55-82], BMI 28 [16-39], female 47%, 42% of the tumors were distal) and 159 age and sex matched controls. 87 of the control patients had a negative colonoscopy finding (cNEG), 19 had hyperplastic polyps (HP), 37 had small non-advanced adenomas (NAA) and 16 were diagnosed with other benign gastrointestinal diseases (GID). The model correctly classified 92% (33/36) of CRC patients. Sensitivity per cancer stage ranged from 83% (5/6) for stage I, 92% (11/12) for stage II, 92% (12/13) for stage III to 100% (5/5) for stage IV. Specificity of the model was 97% (154/159), with 100% (37/37) NAA, 94% (15/16) GID, 95% (18/19) HP and 97% cNEG patients correctly identified. Lesion location, gender, BMI, age and country of origin were not significantly correlated to prediction outcome. Conclusions: Methylation sequencing data analyzed using read-wise scoring approach combined with a machine-learning algorithm is highly diagnostic for early-stage (I-II) CRCs (89% sensitivity at 97% specificity). This method could serve as the basis for a highly accurate and minimally invasive blood-based CRC screening test with significant implications for the clinical utility of ctDNA in early-stage cancer detection.

oncology
Abstract 2307: Targeted cell-free DNA methylation signature in metastatic castration-resistant prostate cancer

Jodie Wong,Yijun Tian,Amir Bitaraf,Claire Hanson,Matthew Larson,Jennifer Lloyd,Julia Batten,Neeraj Agarwal,Umang Swami,Anna Neibling,Jonathan Tward,Benjamin Maughan,Sumati Gupta,Manish Kohli,Liang Wang

DOI: https://doi.org/10.1158/1538-7445.am2023-2307

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Background: DNA methylation of cytosines in CpG sites serves as an important epigenetic regulator for gene expression. In prostate cancer (PC), differences in DNA methylation regions have been observed between normal and tumor cells. However, acquiring the samples to study these patterns can be challenging through standard biopsies. Therefore, liquid biopsies provide a minimally invasive method which can be utilized to investigate the methylome of PC patients. In this study, we used liquid biopsies from a well-defined group of PC patients to examine cell-free DNA (cfDNA) methylation signatures and determine their clinical significance in metastatic castration-resistant prostate cancer. Methods: Plasma was prospectively collected from a cohort 108 PC patients representing localized PC (n=24), metastatic hormone-sensitive PC (mHSPC) (n=28), and metastatic castration resistant PC (mCRPC) (n=37 pre-, n=19 post- mCRPC treatments). cfDNA from the patient plasma was used for an enzymatic methylation sequencing (EM-seq) that targeted a panel of genes (n=441) implicated in prostate cancer biology. Methylation status at CpG islands of these genes were examined using Twist targeted cfDNA methylation assay. The Bismark program was used for methylation calling. Differentially methylated regions (DMRs) across various patient outcomes were assessed by linking the CpG methylation data from target genes to the associated clinical data. Results: We identified DMRs in 305 out of the 411 target genes in the plasma epigenome when comparing the mCRPC to non-mCRPC states (localized PC and mHSPC) (false discovery rate, FDR < 0.2). From these 305 genes, we found that in patients experiencing only PSA relapse after failure of mHSPC (biochemical mCRPC) versus patients with clinical progression (clinical mCRPC), 261 out of the 305 genes had DMRs (p <0.05). We also compared DMRs before and after 3-months of treatment in the mCRPC state and found that 175 out of the 305 genes showed significant changes after 3-months of mCRPC-specific treatment. Furthermore, from these 175 genes, 24 genes showed significant methylation differences when comparing patients with and without disease progression during mCRPC treatment and 20 genes showed significant differences when comparing patients with neuroendocrine features to those with common adenocarcinoma of PC at the mCRPC state (p<0.05). These differentially methylated genes include RUNX3, FOXA2, HIC1 and MYCN. Conclusions: cfDNA-based liquid biopsies provide a minimally invasive method to investigate the methylome of mCRPC patients. Our observations that cfDNA methylation was correlated with disease progression provide evidence that DMRs across a select panel of genes may serve as predictive biomarker for poor response to therapy and survival. Citation Format: Jodie Wong, Yijun Tian, Amir Bitaraf, Claire Hanson, Matthew Larson, Jennifer Lloyd, Julia Batten, Neeraj Agarwal, Umang Swami, Anna Neibling, Jonathan Tward, Benjamin Maughan, Sumati Gupta, Manish Kohli, Liang Wang. Targeted cell-free DNA methylation signature in metastatic castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2307.

oncology
Cytomegalovirus-induced interstitial pneumonitis in a patient with systemic lupus erythematosus.

Y. Tokunaga,K. Takenaka,R. Asayama,T. Shibuya

DOI: https://doi.org/10.2169/INTERNALMEDICINE.35.517

1996-06-01

Internal Medicine

Abstract:We report an unusual case of cytomegalovirus (CMV) interstitial pneumonitis (IP) occurring in a 51-year-old Japanese woman with systemic lupus erythematosus (SLE). She developed hypoxemia after intensive immunosuppressive therapy with prednisolone and cyclophosphamide. Fine crackles were audible in the lower lungs bilaterally. Chest X-ray and computed tomography confirmed the presence of IP. CMV-antigenemia was confirmed by immunological staining of leukocytes using the peroxidase-labeled monoclonal antibody, HRP-C7. Hypoxemia improved gradually on methylprednisolone pulse therapy and gancyclovir, and CMV-antigen positive leukocytes disappeared from the peripheral blood. Data suggest the importance of CMV as a cause of IP in SLE, and the usefulness of the assay for CMV-antigenemia with C7-HRP for rapid diagnosis.
Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation

Shaobo Mo,Li Ye,Dongyang Wang,Lingyu Han,Shuang Zhou,Hui Wang,Weixing Dai,Yichao Wang,Wenqin Luo,Renjie Wang,Ye Xu,Sanjun Cai,Rui Liu,Zheng Wang,Guoxiang Cai

DOI: https://doi.org/10.1001/jamaoncol.2023.0425

IF: 33.006

2023-04-20

JAMA Oncology

Abstract:Importance Detection of molecular residual disease and risk stratification as early as possible may improve the treatment of patients with cancer. Efficient pragmatic tests are therefore required. Objective To measure circulating tumor DNA (ctDNA) with 6 DNA methylation markers in blood samples and to evaluate the association of the presence of ctDNA with colorectal cancer (CRC) recurrence throughout the disease course. Design, Setting, and Participants In this multicenter prospective longitudinal cohort study performed from December 12, 2019, to February 28, 2022, 350 patients with stage I to III CRC were recruited from 2 hospitals for collection of blood samples before and after surgery, during and after adjuvant chemotherapy, and every 3 months for up to 2 years. A multiplex, ctDNA methylation, quantitative polymerase chain reaction assay was used to detect ctDNA in plasma samples. Results A total of 299 patients with stage I to III CRC were evaluated. Of 296 patients with preoperative samples, 232 (78.4%) tested positive for any of the 6 ctDNA methylation markers. A total of 186 patients (62.2%) were male, and the mean (SD) age was 60.1 (10.3) years. At postoperative month 1, ctDNA-positive patients were 17.5 times more likely to relapse than were ctDNA-negative patients (hazard ratio [HR], 17.5; 95% CI, 8.9-34.4; P &lt; .001). The integration of ctDNA and carcinoembryonic antigen tests showed risk stratification for recurrence with an HR of 19.0 (95% CI, 8.9-40.7; P &lt; .001). Furthermore, ctDNA status at postoperative month 1 was strongly associated with prognosis in patients treated with adjuvant chemotherapy of different durations and intensities. After adjuvant chemotherapy, ctDNA-positive patients had a significantly shorter recurrence-free survival than did the ctDNA-negative patients (HR, 13.8; 95% CI, 5.9-32.1; P &lt; .001). Longitudinal ctDNA analysis after the postdefinitive treatment showed a discriminating effect in that ctDNA-positive patients had poorer recurrence-free survival than did the ctDNA-negative patients (HR, 20.6; 95% CI, 9.5-44.9; P &lt; .001). The discriminating effect was enhanced (HR, 68.8; 95% CI, 18.4-257.7; P &lt; .001) when ctDNA status was maintained longitudinally. Postdefinitive treatment analysis detected CRC recurrence earlier than radiologically confirmed recurrence, with a median lead time of 3.3 months (IQR, 0.5-6.5 months). Conclusions and Relevance The findings of this cohort study suggest that longitudinal assessment of ctDNA methylation may enable the early detection of recurrence, potentially optimizing risk stratification and postoperative treatment of patients with CRC.

oncology
DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer.

Wei Zhang,Jinke Sui,Xianrui Wu,Fuao Cao,Guanyu Yu,Chenyang Wang,Zhihong Zhang,Bingsi Li,Shuai Fang,Han Han-Zhang,Zheng Lou,Haifeng Gong,Lianjie Liu,Nanxin Zheng,Liqiang Hao,Ping Lan

DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.e15076

IF: 45.3

2019-10-07

Journal of Clinical Oncology

Abstract:e15076 Background: Colorectal cancer (CRC) develops as a result of neoplastic progression, which often takes decades, providing a window for early detection. Unfortunately, there has been little success in developing blood-based screening method due to the low amount of ctDNA present in the circulation, especially in patients with early stage disease. The role of aberrant DNA methylation, occurring very early in tumorigenesis, has been well elucidated. In this prospective study, we evaluated the potentiality of DNA methylation status obtained from ctDNA as an early detection method. Methods: Panel Design: Methylation data of tumor samples (12 types, n = 4,772), adjacent normal (8 types, n = 411), and normal white blood cells (n = 656) from TCGA and GSE were compared. Differentially methylated sites were extracted using modified wald-test with an adjusted p-value 2. Our panel covers 80,672 CpG sites, spanning 1.05Mb of human genome. We performed targeted bisulfite sequencing on plasma samples of 67 (stage I: 13, II:29, III: 23, IV: 2) Chinese CRC patients and 144 healthy individuals to construct a model for deriving markers that are differentially methylated and their associated weight. The model was validated in 2 independent cohorts. Results: We constructed a model using a support vector machine (SVM)-based machine learning classifier based on top 4,000 differentially methylated regions (DMRs) selected by random forest between tumor and normal plasma samples. Subsequently, 5-fold cross-validation with 100-time repeats were performed to gain a robust estimation of model performance, achieving a sensitivity of 91%, specificity of 98% and area under curve (AUC) of 98.6%. The model was subsequently validated in 2 independent cohorts: one consisted of 57 stage I-III CRC patients and 74 healthy individuals and another one with 47 stage IV patients and the same 74 healthy individuals. The model yielded a sensitivity of 83% and 95% for the early and late stage cohorts, respectively. A specificity of 95% was obtained for both cohorts. Conclusions: Our findings demonstrated the potential of profiling DNA methylation, which can effectively distinguish cancerous from healthy, for the purpose of screening. This method has potential to serve as a supplementary or alternative approach in early detection.

oncology
Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction

Farah J. Nassar,Zahraa S. Msheik,Rihab R. Nasr,Sally N. Temraz

DOI: https://doi.org/10.1186/s13148-021-01095-5

2021-05-17

Clinical Epigenetics

Abstract:Abstract Worldwide, colorectal cancer (CRC) is a deadly disease whose death rate ranks second among cancers though its incidence ranks third. Early CRC detection is key and is associated with improved survival outcomes. However, existing tests for CRC diagnosis have several weaknesses thus rendering them inefficient. Moreover, reliable prognostic tests that can predict the overall cancer outcome and recurrence of the disease as well as predictive markers that can assess effectiveness of therapy are still lacking. Thus, shifting to noninvasive liquid biopsy or blood-based biomarkers is vital to improving CRC diagnosis, prognosis, and prediction. Methylated circulating tumor DNA (ctDNA) has gained increased attention as a type of liquid biopsy that is tumor-derived fragmented DNA with epigenetic alterations. Methylated ctDNA are more consistently present in blood of cancer patients as compared to mutated ctDNA. Hence, methylated ctDNA serves as a potential biomarker for CRC that is worth investigating. In this review, we explore what has been reported about methylated ctDNA as a biomarker for CRC diagnosis that can distinguish between CRC patients or those having adenoma and healthy controls as validated specifically through ROC curves. We also examine methylated ctDNA as a biomarker for CRC prognosis and prediction as confirmed through robust statistical analyses. Finally, we discuss the major technical challenges that limits the use of methylated ctDNA for clinical application and suggest possible recommendations to enhance its usage.

oncology,genetics & heredity
A pilot study on ultra-sensitive circulating tumor DNA detection with a novel methylation amplifier probe in colorectal cancer.

Guanyi Xie,Yangjunyi Li,Xiaowen He,Shuang Guo,Liyuan Zhao,Lingjian Yang,Yalong Zhang,Min Li,Xueguang Sun,Ping Lan

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.10547

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:10547 Background: Liquid biopsy is extensively researched for detecting cancer-related methylation markers. However, detecting ultra-low methylation signals in liquid biopsies is extremely challenging. In early-stage cancer patients, less than 1% of circulating cell-free DNA (cfDNA) is tumor tissue-derived DNA (ctDNA), presenting a low signal-to-noise ratio for effective tumor marker detection. Methods: Here, we introduce Methylation Amplifier Probe for Low-signal Enrichment (MAPLE), a method for designing ultra-short hybrid capture probes (25-55 nt). By reducing the length of the probes, MAPLE enhances their intolerance to DNA base mismatches, thereby significantly improving their ability to specifically bind and enrich the targeted methylation haplotypes. A panel consisting of 13,218 CRC-related methylation haplotypes was constructed for validation. 42 samples from patients with cancer and 43 gender/age matched control samples were processed for the panel validation. All the DNA samples underwent bisulfite conversion, library preparation and parallelly hybridized with two capture panels composed with conventional probes (120 nt) or the MAPLE probes, demonstrating its effectiveness in increasing cancer signal-to-noise ratio in the final NGS data. Results: With MAPLE, in the final NGS data, ratio of CRC-related methylation haplotypes reads (signal) in patient’s plasma samples increased from 7% (conventional) to 28% (MAPLE). At 20M total raw reads (1000x sequencing depth), the MAPLE panel detects over four times the targeted haplotype fragments compared to the conventional panel. For a cohort including 42 patients (I-III:24, IV:18) with CRC and 43 gender/age matched controls, the MAPLE panel aided by a machine-learning classifier detected patients with a sensitivity of 0.83 and a specificity of 0.95. Conclusions: This pilot study highlights the potential of ultra-short probes in capturing cancer-related methylation haplotypes, advancing towards an early detection test for pan-cancer.

oncology
Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.

Jindan Luo,Hang Dong,Haoran Tang,Jiahe Yi,Pan Du,Shidong Jia,Liping Xie

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.275

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:275 Background: Distinguishing between early-stage prostate cancer (PCa) and benign prostatic hyperplasia (BPH) has posed a persistent clinical challenge. Exploring the epigenetic characteristics of urinary cell-free DNA (ucfDNA) offers potential for improving diagnosis. In this preliminary study, we aimed to investigate the feasibility of utilizing of urinary cfDNA methylation features as a non-invasive way to detect PCa. Methods: Paired tissue, plasma, and urine samples were collected from 12 PCa patients, along with paired plasma and urine samples from 12 BPH patients, and urine samples from 24 healthy donors. PredicineEPIC, a whole genome-based DNA methylation assay, was implemented to profile methylation features in all these samples. Results: We discovered that the methylation patterns of ucfDNA more closely resembled those of tumor tissue compared to plasma cfDNA, suggesting that urine can serve as an effectual alternative to blood for detecting cancer related signals. We identified 369 differentially methylated regions that contained PCa-specific methylation signals. Subsequently, we employed feature selection and applied a machine learning regression algorithm to construct a classification model. Validation on an independent GEO dataset yielded an impressive AUC of 0.83 for distinguishing between PCa and benign prostatic hyperplasia (BPH). Conclusions: This study demonstrated the potential of ucfDNA-based methylation markers in the early detection of prostate cancer.

oncology
Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis

Morten Borg,Sara Witting Christensen Wen,Rikke Fredslund Andersen,Signe Timm,Torben Frøstrup Hansen,Ole Hilberg

DOI: https://doi.org/10.3390/cancers15153959

2023-08-04

Cancers

Abstract:Lung cancer is the leading cause of cancer-related deaths, and early detection is crucial for improving patient outcomes. Current screening methods using computed tomography have limitations, prompting interest in non-invasive diagnostic tools such as methylated circulating tumor DNA (ctDNA). The PRISMA guidelines for systematic reviews were followed. The electronic databases MEDLINE, Embase, Web of Science, and Cochrane Library were systematically searched for articles. The search string contained three main topics: Lung cancer, blood, and methylated ctDNA. The extraction of data and quality assessment were carried out independently by the reviewers. In total, 33 studies were eligible for inclusion in this systematic review and meta-analysis. The most frequently studied genes were SHOX2, RASSF1A, and APC. The sensitivity and specificity of methylated ctDNA varied across studies, with a summary sensitivity estimate of 46.9% and a summary specificity estimate of 92.9%. The area under the hierarchical summary receiver operating characteristics curve was 0.81. The included studies were generally of acceptable quality, although they lacked information in certain areas. The risk of publication bias was not significant. Based on the findings, methylated ctDNA in blood shows potential as a rule-in tool for lung cancer diagnosis but requires further research, possibly in combination with other biomarkers.

oncology
Circulating tumor DNA methylation marker-based minimal residual diseases detection and recurrence monitoring of cancer.

Huiyong Wang,Xiaobao Pan,Lin Wang,Chao Li,Chao Ma,Shuai Yu,Fanyang Meng,Jing Liu,Liang Liu,Zhanbo Cao

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e15172

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e15172 Background: Circulating tumor DNA (ctDNA) has been heralded as a promising tool to detect residual disease, relapse, and monitor treatment response by detecting molecular residual disease (MRD) in solid tumors. Numerous previous studies have demonstrated the molecular characteristics of ctDNA, such as the mutational landscape, single-nucleotide variations, copy number variations, and methylation landscape. Based on the methylation characteristics of ctDNA, we developed a novel MRD evaluation system (PcMM-qMSP) with ctDNA methylation markers, and evaluated the association of changes in ctDNA level with clinical outcome. Methods: We used sequencing data from public databases for data mining by clinical Natural Language Processing (NLP) to screen the pan-cancer ctDNA methylation markers (PcMM). A PcMM-based MRD detection method was established by quantitative methylation-specific PCR (qMSP). Moreover, 99 clinical blood samples [lung cancer (41), colorectal cancer (18), gastric cancer (5), pancreatic adenocarcinoma (16), liver cancer (6), cervical cancer (3), ovarian cancer (4), breast cancer (3), and unknown (3)] were collected to evaluate the consistency of ctDNA level between PcMM-qMSP and next-generation sequencing (NGS). Results: We evaluated the precision, including within-batch (intra) and between-batch (inter) reproducibility. PcMM-qMSP showed coefficients of variation (CVs) of the intra- and inter-batch assay of 0.42-0.65% and 0.05-0.27%, the accuracies were 100%. Best-in-class assays demonstrated a limit of detection (LoD) of approximately 30 copies of methylated DNA, with lower LoD at 10 copies. The evaluation results of 99 pan-solid tumor blood samples showed that the consistency of PcMM-qMSP and NGS in ctDNA level assessment was 0.82. The specific data are shown in the Table. Conclusions: PcMM is a pan-tumor specific methylation biomarker. The results demonstrated that PcMM-qMSP and NGS were highly functionally consistent for estimating ctDNA level. PcMM-qMSP detection time is less than 24 hours and costs USD 300 as compared to NGS, which takes seven days and costs USD 900. Hence, PcMM-qMSP is economical, rapid, accurate and highly sensitive for detecting pan-solid tumors. [Table: see text]

oncology
The development and validation of a novel targeted methylation sequencing technology detecting 0.003 percent tumor signal in early-stage cancer plasma.

Grace Q. Zhao,Yun Bao,Heng Wang,Jianmin Wang,Shengrong Lin

DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.4092

IF: 45.3

2020-05-26

Journal of Clinical Oncology

Abstract:4092 Background: Methylation analysis in cell-free DNA holds great potential for early cancer detection. In the plasma of early stage cancer patient, the tumor content is estimated to be less than 0.1%, therefore demands a highly sensitive assay. Targeted Methylation Sequencing (TMS) is the most promising approach; however, the current sensitivity and specificity are compromised by low efficiency and low recovery of target enrichment, and further hampered by background noise associated with large panels. The ideal solution would be an in-depth analysis using a focused small cancer-specific methylation biomarker panel, but is not supported by existing technologies. Methods: Here we present a new technology designed for TMS analysis in cfDNA: Point-n-Seq, featuring an enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Particularly, this technology enables small focused panel that interrogates the methylation status of 1 to ~1000 markers. We designed a CRC panel covering 100 methylation markers in 3 steps: identify ~1000 CRC-specific markers from public databases; eliminate makers with high background signal in baseline cfDNA of healthy population; finalize the list with the most differentiating markers between patient and healthy cfDNA. Results: The capture of Point-n-Seq CRC panel is highly efficient resulting in high uniformity (94% > 0.5X) and on-target rate ( > 80%). For 20 ng cfDNA input, more than 1000 deduped informative reads were obtained for each marker on average, despite the high GC content ( > 80%). The output of informative reads was linear to the cfDNA input ranging from 1 ng to 40 ng. In titration studies, 0.6 pg (0.2X genome equivalent) methylated DNA in 20 ng cfDNA (0.003%) was reliably detected over cfDNA background. Using plasma samples from patients with CRC - early stage (I, n = 7; II, n = 7), late stage (III, n = 11; IV, n = 3), and control individuals (n = 105), the average fractions of methylated signal are 0.0034%, 0.013%, 0.09%, 0.17%, 0.29% for control, stage I, II, III, IV accordingly. With a simple cut-off using methylation fraction, Point-n Seq CRC panel achieved a sensitivity of 86% for stage I, 100% for stage (II-IV) at a specificity of 91%, with AUC = 0.96. Conclusions: Point-n-Seq TMS is the first hybridization based NGS technology enables the small focused methylation panel (e.g. 100 markers) sequencing using cfDNA, and it will greatly facilitate the development of practical and cost-effective methylation assays for clinical use.

oncology
DNA Methylation Cancer Biomarkers: Translation to the Clinic

Warwick J. Locke,Dominic Guanzon,Chenkai Ma,Yi Jin Liew,Konsta R. Duesing,Kim Y.C. Fung,Jason P. Ross

DOI: https://doi.org/10.3389/fgene.2019.01150

IF: 3.7

2019-11-14

Frontiers in Genetics

Abstract:Carcinogenesis is accompanied by widespread DNA methylation changes within the cell. These changes are characterized by a globally hypomethylated genome with focal hypermethylation of numerous 5'-cytosine-phosphate-guanine-3' (CpG) islands, often spanning gene promoters and first exons. Many of these epigenetic changes occur early in tumorigenesis and are highly pervasive across a tumor type. This allows DNA methylation cancer biomarkers to be suitable for early detection and also to have utility across a range of areas relevant to cancer detection and treatment. Such tests are also simple in construction, as only one or a few loci need to be targeted for good test coverage. These properties make cancer-associated DNA methylation changes very attractive for development of cancer biomarker tests with substantive clinical utility. Across the patient journey from initial detection, to treatment and then monitoring, there are several points where DNA methylation assays can inform clinical practice. Assays on surgically removed tumor tissue are useful to determine indicators of treatment resistance, prognostication of outcome, or to molecularly characterize, classify, and determine the tissue of origin of a tumor. Cancer-associated DNA methylation changes can also be detected with accuracy in the cell-free DNA present in blood, stool, urine, and other biosamples. Such tests hold great promise for the development of simple, economical, and highly specific cancer detection tests suitable for population-wide screening, with several successfully translated examples already. The ability of circulating tumor DNA liquid biopsy assays to monitor cancer in situ also allows for the ability to monitor response to therapy, to detect minimal residual disease and as an early biomarker for cancer recurrence. This review will summarize existing DNA methylation cancer biomarkers used in clinical practice across the application domains above, discuss what makes a suitable DNA methylation cancer biomarker, and identify barriers to translation. We discuss technical factors such as the analytical performance and product-market fit, factors that contribute to successful downstream investment, including geography, and how this impacts intellectual property, regulatory hurdles, and the future of the marketplace and healthcare system.

genetics & heredity
Refereed paper: An access control scheme based on Chinese remainder theorem and time stamp concept

M. Hwang,Wen-Guey Tzeng,Wei-Pang Yang

DOI: https://doi.org/10.1016/0167-4048(95)00028-3

Abstract:
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study

Deb Schrag,Tomasz M Beer,Charles H McDonnell 3rd,Lincoln Nadauld,Christina A Dilaveri,Robert Reid,Catherine R Marinac,Karen C Chung,Margarita Lopatin,Eric T Fung,Eric A Klein

DOI: https://doi.org/10.1016/S0140-6736(23)01700-2

2023-10-07

Abstract:Background: Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study investigating the feasibility of MCED testing for cancer screening. Methods: In this prospective cohort study done in oncology and primary care outpatient clinics at seven US health networks, a convenience sample of adults aged 50 years or older without signs or symptoms of cancer consented to MCED testing. We collected blood, analysed cfDNA, and returned results to participants' doctors. If a methylation signature indicative of cancer was detected, predicted cancer signal origin(s) informed diagnostic assessment. The primary outcome was time to, and extent of, diagnostic testing required to confirm the presence or absence of cancer. This trial is registered at ClinicalTrials.gov, NCT04241796, and is completed. Findings: Between Dec 12, 2019, and Dec 4, 2020, we recruited 6662 participants. 4204 (63·5%) of 6621 participants with analysable results were women, 2417 (36·5%) were men, and 6071 (91·7%) were White. A cancer signal was detected in 92 (1·4%) of 6621 participants with analysable results. 35 (38%) participants were diagnosed with cancer (true positives) and 57 (62%) had no cancer diagnosis (false positives). Excluding two participants whose diagnostic assessments began before MCED test results were reported, median time to diagnostic resolution was 79 days (IQR 37-219): 57 days (33-143) in true-positive and 162 days (44-248) in false-positive participants. Most participants had both laboratory tests (26 [79%] of 33 with true-positive results and 50 [88%] of 57 with false-positive results) and imaging (30 [91%] of 33 with true-positive results and 53 [93%] of 57 with false-positive results). Fewer procedures were done in participants with false-positive results (17 [30%] of 57) than true-positive results (27 [82%] of 33) and few had surgery (one with a false-positive result and three with a true-positive result). Interpretation: This study supports the feasibility of MCED screening for cancer and underscores the need for further research investigating the test's clinical utility. Funding: GRAIL.

Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.

Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer

Abstract 1264: A targeted methylation-based multi-cancer early detection blood test preferentially detects high-grade prostate cancer and minimizes overdiagnosis

Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients

Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation

Highly Specific Multiplex DNA Methylation Detection for Liquid Biopsy of Colorectal Cancer

Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach

Accurate early-stage colorectal cancer detection through analysis of cell-free circulating tumor DNA (ctDNA) methylation patterns.

Abstract 2307: Targeted cell-free DNA methylation signature in metastatic castration-resistant prostate cancer

Cytomegalovirus-induced interstitial pneumonitis in a patient with systemic lupus erythematosus.

Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation

DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer.

Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction

A pilot study on ultra-sensitive circulating tumor DNA detection with a novel methylation amplifier probe in colorectal cancer.

Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis

Circulating tumor DNA methylation marker-based minimal residual diseases detection and recurrence monitoring of cancer.

The development and validation of a novel targeted methylation sequencing technology detecting 0.003 percent tumor signal in early-stage cancer plasma.

DNA Methylation Cancer Biomarkers: Translation to the Clinic

Refereed paper: An access control scheme based on Chinese remainder theorem and time stamp concept

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study